参考文献/References:
[1] Czernin J,Satvamurthy N,Schiepers C.Molecular mechanisms of bone 18F-NaF deposition[J].J Nucl Med,2010,51(12):1826-1829.
[2] Blau M,Nagler W,Bender MA.Fluorine-18:a new isotope for bone scanning[J].J Nucl Med,1962,3:332-4.
[3] Segall G,Delbeke D,Stabin MG,et al.SNM practice guideline for Sodium F-18-Fluoride PET/CT bone scans 1.0[J].J Nuc Med,2010,51(11):1813-1820.
[4] Segall GM.PET/CT with sodium 18F-fluoride for management of patients with prostate cancer[J].J Nucl Med,2014,55(4):531-533.
[5] Frost ML,Compston JE,Goldsmith D,et al.18F-fluoride positron emission tomographv measurements of regional bone formation in hemodialvsis patients with suspected advnamic bone disease[J].Calcif Tissue Int,2013,93(5):436-447.
[6] Grant FD,Fahey FH,Packard AB,et al.Skeletal PET with F-18-fluoride:Applving new technologv to an old tracer[J].J Nuclr Med,2008,49(1):68-78.
[7] Caldarella C,Treglia G,Giordano A,et al.W hen to perform positron emission tomography/computed tomography or radionu-clide bone scan in patients with recently diagnosed prostate cancer[J].Cancer Manag Res,2013,5(6):123-131.
[8] Tateishi U,Morita S,Taguri M,et al.A meta-analysis of 18F-Fluo-ride positron emission tomography for assessment of metastatic bone tumor[J].Ann Nucl Med,2010,24(7):523-531.
[9] Damle NA,Bal C,Bandopadhyaya GP,et al.The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast,lung and prostate carcinoma:a comparison with F D G PET/CT and 99mTc-MDP bone scan[J].Jpn J Radiol,2013,31(4):262-269.
[10] Bastawrous S,Bhargava P,Behnia F,et al.Newer PET application with an old tracer:role of 18F-NaF skeletal PET/CT in oncologic practice[J].Radiographics,2014,34(5):1295-1316.
[11] Doot RK,Muzi M,Peterson LM,et al.Kinetic analysis of 18F-fluo-ride PET images of breast cancer bone metastases[J].J Nucl Med,2010,51(4):521-527.
[12] Tarnawska-Pierscinska M,Holody L,Braziewicz J,et al.Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG[J].Nucl Med Rev Cent East Eur,2011,14(2):105-108.
[13] Kawaguchi M,Tateishi U,Shizukuishi K,et al.18F-fluoride uptake in bone metastasis:morphologic and metabolic analysis on inte-grated PET/CT[J].Ann Nucl Med,2010,24(4):241-247.
[14] Schirrmeister,H,Guhlmann,A,Kotzerke,J,et al.Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography[J].J Clin Oncol,1999,17(8):2381-2389.
[15] Yoon SH,Kim KS,Kang SY,et al.Usefulness of 18F-fluoride PET/CT in breast cancer patients with osteosclerotic bone metastases[J].Nucl Med Mol Imaging,2013,47(1):27-35.
[16] Iagaru A,Mittra E,Mosci C,et al.Combined F-18-Fluoride and F-18-FDg PET/CT scanning for evaluation of malignancy:results of an international multicenter trial[J].J NuclMed,2013,54(2):176-183.
[17] Lin FI,Rao JE,Mittra ES,et al.Prospective comparison of com-bined 18F-FDG and 18F-NaF PET/CT vs.18F-FDG PET/CT imaging for detection of malignancy[J].Eur J Nucl Med Mol Imaging,2012,39(2):262-270.
[18] Schirrmeister H,Glatting G,Hetzel J.Prospective evaluation of the clinical value of planar bone scans,SPEl T,and 18F-labeled NaF PET in newly diagnosed lung cancer[J].J Nucl Med,2001,42(12):1800-1804.
[19] Even-Sapir E,Metser U,Mishani E,et al.The detection of bone metastases in patients with high-risk prostate cancer:Tc-99m-MDP planar bone scintigraphy,single-and multi-field-of-view SPECT,F-18-fluoride PET,and F-18-fluoride PET/CT[J].J Nucl Med,2006,47(2):287-297.
[20] Hillner BE,Siegel BA,Hanna L,et al.Impact of 18F-fluoride PET in patients with known prostate cancer:initial results from the N a-tional Oncologic PET Registry[J].J Nucl Med,2014,55(4):574-581.
[21] Jadvar H,Desai B,Ji L,et al.Prospective evaluation of 18F-NaF and18F-FDG PET/CT:in detection of occult metastatic disease in biochemical recurrence of prostate cancer[J].Clin Nucl Med,2012,37(7):637-643.
[22」Mosavi F,Johansson S,Sandberg DT,et al.Whole-body diffusion-weighted MRI compared with F-18-NaF PET/CT for detection of bone metastases in patients with High-Risk prostate carcinoma[J].AmJRoentgenol,2012,199(5):1114-1120.
[23] Hillner BE,Siegel BA,Hanna L,et al.Impact of 18F-Fluoride PET on intended management of patients with cancers other than prostate cancer:results from the national oncologic PET registry[J].J Nucl Med,2014,55(7):1054-1061.
[24] Sharma P,Karunanithi S,Chakraborty PS,et al.18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carci-noma:a pilot study[J].Nucl Med Commun,2014,35(12):1247-1253.
[25] Chan SC,Wang HM,Ng SH,et al.Utility of 18-Fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in height-ened-risk head and neck cancer patients[J].J Nucl Med,2012,53(11):1730-1735.
[26] Ota N,Kato K,Iwano S,et al.Comparison of 18F-fluoride PET/CT,18F-FDG PET/CT and bone scintigraphy(planar and SPECT) in de-tection of bone metastases of differentiated thyroid cancer:a pilot study[J/OL].Br J Radiol,2014,87(1034):20130444[2014-11-30].http://www.ncbi.nlm.nih.gov/pubmed/?term=24297809.
[27] Chakraborty D,Bhattacharya A,Mete UK,et al.Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma[J].Clin Nucl Med,2013,38(8):616-621.
[28] Avery R,Kuo PH.18F Sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound[J].Clin Nucl Med,2013,38(9):746-748.
[29] Sharma S.Imaging and intervention in prostate cancer:Current perspectives and future trends[J].Indian J Radiol Imaging,2014,24(2):139-148.
[30] Iagaru A,Young P,Mittra E,et al.Pilot prospective evaluation of 99mTc-MDP scintigraphy,18F NaF PET/CT,18F FDG PET/CT andwhole-body MRI for detection of skeletal metastases[J/OL].Clin Nucl Med,2013,38(7):e290-e296[2014-11-30].http://www.ncbi.nlm.nih.gov/pubmed/?term=23455520.
[31] Iagaru A,Mittra E,Dick DW,et al.Prospective evaluation of 99mTc MDP scintigraphy,18F NaF PET/CT,and 18F FDG PET/CT for de-tection of skeletal metastases[J].Mol Imaging Biol,2012,14(2):252-259.
[32] Shen CT,Qiu ZL,Han TT,et al.Performance of 18F-Fluoride PET or PET/CT for the detection of bone metastases:a meta-analysis[J].Clin Nucl Med,2015,40(2):103-110.
[33] Iagaru A,Mittra E,Yaghoubi SS,et al.Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignan-cy:results of the pilot-phase study[J].J Nucl Med,2009,50(4):501-505.
[34] Sampath SC,Sampath SC,Mosci C,et al.Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone[J/OLj.Clin Nucl Med,2015,40(3):e173-177[2014-11-30],http://www.ncbi.nlm.nih.gov/pubmed/?term=25140557.
[35] Harisankar CN,Agrawal K,Bhattacharya A,et al.F-18 fluoro-de-oxy-glucose and F-18 sodium fluoride cocktail PET/CT scan in pa-tients with breast cancer having equivocal bone SPECT/CT[J].Indi-an J Nucl Med,2014,29(2):81-86.
[36] 王俊起,高硕.PET评价骨转移瘤[J].国际放射医学核医学杂志,2006,30(2):87-90.
[37] Drubach LA,Connolly SA,Palmer EL,et al.Skeletal scintigraphy with 18F-NaF PET for the evaluation of bone pain in children[J].Am J Roentgenol,2011,197(3):713-719.
[38] Lee SJ,Lee WW,Kim SE.Bone positron emission tomography with or without CT is more accurate than bone scan for detection of bone metastasis[J].Korean J Radiol,2013,14(3):510-519.
相似文献/References:
[1]任越,张慧芳,胡波,等.电离辐射诱导小鼠骨电子顺磁共振信号检测的影响因素[J].国际放射医学核医学杂志,2015,39(5):371.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 004]
ren yue,zhang huifang,hu bo,et al.influencing factors of detection on ionizing radiation-induced electron paramagnetic resonance signal in bones[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):371.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 004]
[2]郝新忠,武志芳,武萍,等.SAPHO综合征18F-FDG PET/CT显像和临床分析[J].国际放射医学核医学杂志,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
Hao Xinzhong,Wu Zhifang,Wu Ping,et al.18F-FDG PET/CT imaging and clinical features of SAPHO syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
[3]白剑强,夏群,胡永成.放射性核素骨显像在脊柱转移瘤诊断中的价值[J].国际放射医学核医学杂志,2011,35(1):28.[doi:10.3760/cma.j.issn.1673-4114.2011.01.008]
BAI Jian-qiang,XIA Qun,HU Yong-cheng.Evaluate the diagnostic value of radionuclide bone imaging of metastatic spine tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):28.[doi:10.3760/cma.j.issn.1673-4114.2011.01.008]
[4]徐海青,段俊,吴边.全身骨显像诊断前列腺癌骨转移与PSA水平及病理分级的相关性研究[J].国际放射医学核医学杂志,2011,35(1):34.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]
XU Hai-qing,DUAN Jun,WU Bian.Study of relationship between the bone imaging, level of PSA and pathology grade in diagnosis of prostate carcinoma bone metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):34.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]
[5]陶欣慰,黄钢.18F-FDGPET与99Tcm-MDP骨显像在诊断肿瘤骨转移中的比较[J].国际放射医学核医学杂志,2010,34(6):352.[doi:10.3760/cma.j.issn.1673-4114,2010.06.008]
TAO Xin-wei,HUANG Gang.Comparasion of 18F-FDG PET and 99Tcm-MDP bone imaging in diagnosis of bone metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):352.[doi:10.3760/cma.j.issn.1673-4114,2010.06.008]
[6]段钰,邓小虎,赵增鹏,等.左股骨朗格汉斯细胞组织细胞增生症PET/CT显像一例[J].国际放射医学核医学杂志,2017,41(6):452.[doi:10.3760/cma.j.issn.1673-4114.2017.06.013]